Abstract
Transfer of the sodium iodide symporter (hNIS) has been proposed as a new principle of cancer gene therapy. Using clinically relevant doses of 131I for the treatment of NIS-expressing prostate carcinoma cells, we investigated the kinetics and the absorbed doses obtained in these tumors. hNIS-expressing cell lines accumulated up to 200 times more iodide when compared to wild-type cells. However, a rapid efflux of the radioactivity (80%) occurred during the first 20 min after replacement of the medium. In rats, the hNIS-expressing tumors accumulated up to 20 times more iodide when compared to contralateral transplanted wild-type tumors. After 24 h and doses of 550, 1200 or 2400 MBq/m2 hNIS-expressing tumors lost 89, 89 and 91% of the initial activity, respectively. Dosimetric calculations showed that 1200 MBq/m2 resulted in 3±0.5 Gy (wild-type tumor 0.15±0.1 Gy) and 2400 MBq/m2 resulted in 3.1±0.9 Gy (wild-type tumor 0.26±0.02 Gy). Although transduction of the hNIS gene induces iodide transport in rat prostate adenocarcinoma a rapid efflux occurs, which leads to a low absorbed dose in genetically modified tumors. With regard to a therapeutic application additional conditions need to be defined leading to iodide trapping.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Marcocci C, Cohen JL, Grollman EF . Effect of actinomycin D on iodide transport in FRTL-5 thyroid cells. Endocrinology 1984; 115: 2123–2132.
Weiss SJ, Philp NJ, Grollman EF . Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology 1984; 114: 1090–1098.
Paire A, Bernier-Valentin F, Selmi-Ruby S, Rousset B . Characterization of the rat thyroid iodide transporter using anti-peptide antibodies. J Biol Chem 1997; 272: 18245–18249.
Nakamura Y, Ohtaki S, Yamazaki I . Molecular mechanism of iodide transport by thyroid plasmalemmal vesicles: cooperative sodium activation and asymmetrical affinities for the ions on the outside and inside of the vesicles. J Biochem 1988; 104: 544–549.
Nakamura Y, Kotani T, Ohtaki S . Transcellular ioide transport and iodination on the apical plasma membrane by mono-layer porcine thyroid cells cultured on collagen-coated fibers. J Endocrinol 1990; 126: 275–281.
Smanik PA et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996; 226: 339–345.
Dai G, Levy O, Carrasco N . Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 458–460.
Boland A et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60: 3484–3492.
Boland A et al. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid 2002; 12: 19–26.
Carlin S et al. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two- and three-dimensional models. Cancer Gene Ther 2000; 7: 1529–1536.
Cho JY et al. Expression and activity of human Na+/I− symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther 2000; 7: 740–749.
Haberkorn U et al. Transfer of the human sodium iodide symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 2001; 42: 317–325.
La Perle KMD et al. In vivo expression and function of the sodium iodide symporter following gene transfer in the MATLyLu rat model of metastatic prostate cancer. Prostate 2002; 50: 170–178.
Mandell RB, Mandell LZ, Link CJ . Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999; 59: 661–668.
Nakamoto Y et al. Establishment and characterization of a breast cancer cell line expressing Na+/I− symporters for radioiodide concentrator gene therapy. J Nucl Med 2000; 41: 1898–1904.
Shimura H et al. Iodide uptake and experimental 131J therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I− symporter gene. Endocrinology 1997; 138: 4493–4496.
Smit JW et al. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid 2000; 10: 939–943.
Smit JWA et al. Iodide kinetics and experimental 131I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab 2002; 87: 1247–1253.
Spitzweg C et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000; 60: 6526–6530.
Spitzweg C et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001; 8: 1524–1531.
Huang M et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 2001; 8: 612–618.
Berman M, Hoff E, Barandes M . Iodine kinetics in man: a model. J Clin Endocrinol Metab 1968; 28: 1–14.
Freireich EJ et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemotherapy Rep 1966; 50: 219–244.
Maxon HR et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309: 937–941.
Haberkorn U et al. Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene. Eur J Nucl Med 2001; 28: 633–638.
Koong S et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84: 912–916.
Urabe M et al. Effect of lithium on function and growth of thyroid cells in vitro. Endocrinology 1991; 129: 807–814.
Lazarus JH . The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 1998; 8: 909–913.
Sedvall G, Jonsson B, Petterson U, Levin K . Effects of lithium salts on plasma protein bound iodine and uptake of 131I in thyroid gland of man and rat. Life Sci 1968; 7: 1257–1264.
Temple R, Berman M, Robbins J, Wolff J . The use of lithium in the treatment of thyrotoxicosis. J Clin Invest 1972; 51: 2746–2756.
Gershengorn MC, Izumi M, Robbins J . Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma. J Clin Endocrinol Metab 1976; 42: 105–111.
Sieger S et al. Tumour specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3). Eur J Nucl Med: in press.
Dadachova E et al. Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol 2002; 29: 13–18.
Petrich T et al. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium iodide symporter. Eur J Nucl Med 2002; 29: 842–854.
Haberkorn U, Altmann A, Eisenhut M . Functional genomics and proteomics – the role of nuclear medicine. Eur J Nucl Med 2002; 29: 115–132.
Pear WS, Nolan GP, Scott ML, Baltimorre D . Production of high titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392–8396.
Kinscherf R et al. Induction of manganese superoxide dismutase by oxidized-LDL – its relevance in atherosclerosis of humans and heritable hyperlipidemic rabbits. FASEB J 1997b; 11: 1317–1328.
Stabin M . MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538–546.
Acknowledgements
We thank Mrs Irmgard Preugschat-Gumprecht and Silke Vorwald for expert assistance with immunocytochemistry and R Kühnlein for his help in performing the animal experiments. We also thank N Morgenthaler and J Struck (BRAHMS Diagnostics, Berlin, Germany) for supplying hNIS antibodies. This study was supported by a grant from the ‘Tumorzentrum Heidelberg/Mannheim’.
This article is dedicated to Harald zur Hausen on the occasion of his retirement as head of the German Cancer Research Center with gratitude and appreciation for 20 years of leadership.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haberkorn, U., Kinscherf, R., Kissel, M. et al. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther 10, 774–780 (2003). https://doi.org/10.1038/sj.gt.3301943
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301943
Keywords
This article is cited by
-
Combining transfer of TTF-1 and Pax-8 gene: a potential strategy to promote radioiodine therapy of thyroid carcinoma
Cancer Gene Therapy (2012)
-
The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging (2008)
-
Iodide sensitizes genetically modified non-small cell lung cancer cells to ionizing radiation
Cancer Gene Therapy (2006)
-
Non-invasive imaging of cardiac transgene expression with PET: comparison of the human sodium/iodide symporter gene and HSV1-tk as the reporter gene
European Journal of Nuclear Medicine and Molecular Imaging (2005)
-
Gene Therapy Progress and Prospects: Noninvasive imaging of gene therapy in living subjects
Gene Therapy (2004)